{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wei F"],"funding":["Natural Science Foundation of Hubei Province","Chinese Society of Clinical Oncology","National Natural Science Foundation of China","Chen Xiaoping Foundation for the development of science and technology of Hubei province"],"pagination":["185"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12101032"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["25(1)"],"pubmed_abstract":["<h4>Background</h4>Despite various treatment strategies, the incidence and mortality of pancreatic cancer (PC) are among the highest for malignant tumors. Furthermore, there is a lack of effective molecular typing and targeted therapy to treat PC subtypes.<h4>Methods</h4>Multiplex immunofluorescence experiments were performed to explore the roles of FAM111B, FANCD2, KRAS and TP53 in human PC tissues. Kaplan-Meier survival curves were generated and a nomogram was prepared for prognostic prediction. Protein correlations were analyzed using human PC tissues and TCGA and GEO data. Pathways analysis, immunoanalysis, and drug susceptibility analysis were performed based on information in the TCGA database.<h4>Results</h4>Our results indicate that expression of FAM111B and FANCD2 is correlated in"],"journal":["Cancer cell international"],"pubmed_title":["FAM111B and FANCD2, a dual expression signature, defines a distinct phenotype of pancreatic cancer."],"pmcid":["PMC12101032"],"funding_grant_id":["2024AFB995","81803009","Y-L2018-003","CXPJJH122006-1027"],"pubmed_authors":["Li W","Feng L","Wei F","Zhou T","Zhang L","Yuan X"],"additional_accession":[]},"is_claimable":false,"name":"FAM111B and FANCD2, a dual expression signature, defines a distinct phenotype of pancreatic cancer.","description":"<h4>Background</h4>Despite various treatment strategies, the incidence and mortality of pancreatic cancer (PC) are among the highest for malignant tumors. Furthermore, there is a lack of effective molecular typing and targeted therapy to treat PC subtypes.<h4>Methods</h4>Multiplex immunofluorescence experiments were performed to explore the roles of FAM111B, FANCD2, KRAS and TP53 in human PC tissues. Kaplan-Meier survival curves were generated and a nomogram was prepared for prognostic prediction. Protein correlations were analyzed using human PC tissues and TCGA and GEO data. Pathways analysis, immunoanalysis, and drug susceptibility analysis were performed based on information in the TCGA database.<h4>Results</h4>Our results indicate that expression of FAM111B and FANCD2 is correlated in","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2026-06-01T15:33:41.441Z","creation":"2026-04-08T13:38:48.122Z"},"accession":"S-EPMC12101032","cross_references":{"pubmed":["40405284"],"doi":["10.1186/s12935-025-03819-6"]}}